리스페리돈이나 올란자핀에서 지프라시돈으로 약물 교체한 정신분열병 환자의 주관적 삶의 질
송진옥, 이종훈, 최태영 et al. · 생물치료정신의학 · 2009
Objectives: The purpose of this study is to assess the subjective quality of life in stable but symptomatic patients with schizophrenia switched from risperidone or olanzapine to ziprasidone. And we investigated how the subjective quality of life is related with depression, drug attitude, drug satisfaction and psychopathology of schizophrenia. Methods: Twenty-three schizophrenic patients in 3 hospitals were switched to an 8-week, open label, flexible dose(80-160㎎/day) of ziprasidone. Psychiatric status was evaluated by Korean version of 4th Revision of Schizophrenia Quality of Life Scale(SQLS-R4K), Korean version of Calgary Depression Scale for Schizophrenia(KCDSS), Korean version of Drug Attitude Inventory(KDAI-10), Drug Satisfaction Questionaire(DSQ), Positive and Negative Syndrome Scale(PANSS), and Clinical Global Impression scale(CGI) at baseline, day 1, week 4 and week 8. Results: Subjective quality of life and depressive symptom were not improved significantly after switching to ziprasidone. Subjective quality of life was related significantly with depressive symptoms and drug attitude, but not drug satisfaction. Subjective quality of life correlated significantly with total scores and positive symptom scores in PANSS and CGI-S. Conclusion: This study suggests that the subjective quality of life of schizophrenia, who had treated by prior atypical antipsychotics, is not influenced significantly by switching to ziprasidone. Active management for depressive and positive symptoms, and drug side effect is recommended to improve patients' quality of life.
Cited by 0 works.